Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | Global differences in cancer drug prices: a comparative analysis

Daniel Goldstein • 3 Jun 2016
ASCO 2016
Breast Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecological Cancer Lung Cancer Skin Cancer

Press brief by Daniel Goldstein, MD of the Rabin Medical Center, Petah Tikva, Israel, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

More from Daniel Goldstein

2:09
Is the current dose of pembrolizumab approved for treating lung cancer too high?
Daniel Goldstein • 2 Jun 2017
2:15
Personalized dosing of pembrolizumab has the potential to save $0.8 billion per year
Daniel Goldstein • 4 Jun 2017
0:52
Cancer care: the need for a cost-effective approach
Daniel Goldstein • 2 Jun 2017
0:51
Are physicians wasting healthcare resources by over-prescribing drugs?
Daniel Goldstein • 2 Jun 2017

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals